CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV

TÜBINGEN, Germany / BOSTON, USA– June 16, 2021 -- CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials